

Singular Health Group Ltd: SHG

ASX Announcement

09 February 2022

SINGULAR HEALTH RECEIVES \$305,055 FROM R&D TAX INCENTIVE REFUND

09 February 2022 – Singular Health Group Ltd (ASX: SHG, “Singular Health” or the “Company”) advises that it has received a \$305,055 R&D tax incentive refund relating to the costs of research and development incurred during the 30 June 2021 Financial Year. The refund is in respect of eligible R&D activities across Singular Health’s medical technology portfolio, including further developments on AI Tools in Spinal and Soft tissue Segmentation.

The R&D tax incentive is an Australian Federal Government program which provides companies with a tax offset for eligible R&D activities. The R&D refund is on the back of a productive campaign of cutting-edge software development working with research agencies, universities, and partner companies.

Commenting on the refund, Singular Health CEO Thomas Hanly said:

“The Federal Government’s continual support of research and development by Australian business is critically important to developing strong capabilities, and key staff and intellectual property within Australia. Singular Health’s ongoing investment in Research and Development is a critical part of our commercialisation strategy and helps us to compete on a global stage”.

“The 2020/21 FY was a major shift for Singular Health as we were able to partner and leverage our expertise and vision with the capabilities of some of Australia’s key research agencies and universities. This has set the ground-work for a research and development program that will include commercial partners as we seek to monetize our research in 2022”.

ENDS

Authorised for ASX release by the Board of Directors

For further information contact:

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Founded in 2017, Singular Health is a medical technology company that has developed and commercialised the proprietary Volumetric Rendering Platform (“VRP”) for the 3D & VR visualisation of anatomy using standard radiological imagery.

Singular Health is committed to developing technologies that provides patients and practitioners alike with access to personalised, enhanced medical data to inform better health decisions and is currently developing and deploying software products that are built upon the proprietary VRP on a global scale through a direct-to-consumer Software-as-a-Service (“SaaS”) model.

About Scan to Surgery:

Scan to Surgery™ is a disruptive technology driven process that revolutionises the planning and execution of surgical procedures, reducing cost and improving patient outcomes. Built on the backbone of MFTP, incorporating 3D/VR scan review with virtual surgical planning software and utilising local additive manufacturing facilities, Scan to Surgery™ aims to rapidly deliver patient-specific solutions.